Free shipping on all orders over $ 500

WAY-362450 (Turofexorate isopropyl)

Cat. No. M2165
WAY-362450 (Turofexorate isopropyl) Structure
Synonym:

XL335; FXR-450

Size Price Availability Quantity
2mg USD 50  USD50 In stock
5mg USD 75  USD75 In stock
10mg USD 100  USD100 In stock
25mg USD 200  USD200 In stock
50mg USD 320  USD320 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

WAY-362450 (Turofexorate isopropyl; XL335) is a synthetic potent agonists of the farnesoid X receptor (FXR). WAY-362450 binds to the ligand-binding domain (LBD) of human FXR. WAY-362450 (XL335) also induced small heterodimer partner (SHP) expression and repressed cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12 alpha-hydroxylase (CYP8B1) expression. Oral administration of WAY-362450 to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Furthermore, treatment of wild type C57BL/6 mice with the FXR agonist WAY-362450, attenuated lipopolysaccharide-induced serum amyloid P component and serum amyloid A3 mRNA levels in the liver.

Customer Product Validations & Biological Datas
Source Biochem Biophys Res Commun (2014). Figure 1. WAY-362450
Method qRT-PCR
Cell Lines Huh7 cells
Concentrations 3 μM
Incubation Time 24 h
Results No significant pathological changes were found and liver lipid staining is minimal in control liver specimens. Feeding 30% fructose for 8 weeks led to a nearly 6-fold increase of lipids contents in serum and liver respectively, and induced significant hepatic steatosis, characterized by the presence of macrovesicular and microvesicular lipid droplets in hepatocytes.
Chemical Information
Molecular Weight 438.47
Formula C25H24F2N2O3
CAS Number 629664-81-9
Solubility (25°C) DMSO 25 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Zhang S, et al. J Hepatol. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

[2] Hartman HB, et al. J Lipid Res. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

[3] Flatt B, et al. J Med Chem. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

[4] Zhang S, et al. Biochem Biophys Res Commun. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.

Related Farnesoid X Receptor Products
ASC-42

ASC-42 is a novel, potentially best-in-class, highly potent and selective non-steroidal FXR agonist that also inhibits the transcription of HBV RNA to hepatitis B surface antigen by inhibiting the transcription of HBV covalent closed-circle DNA (cccDNA) to HBV RNA.

Linafexor

Linafexor is a bile acid receptor (FXR) agonist that may be used in studies related to cholangitis and non-alcoholic steatohepatitis.

MET-409

MET-409 is an oral non-steroidal bile acid receptor FXR agonist for studies related to inflammatory bowel disease and irritable bowel syndrome.

FXR agonist 5

FXR agonist 5 is a FXR agonist.

XJ02862-S2

XJ02862-S2 shows potent FXR agonistic activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: WAY-362450 (Turofexorate isopropyl), XL335; FXR-450 supplier, Farnesoid X Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.